Aegis Capital Starts Evogene Ltd (EVGN) at Buy, $10 PT

July 29, 2021 11:25 AM EDT
Get Alerts EVGN Hot Sheet
Price: $2.87 -1.71%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 16 | Down: 13 | New: 52
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Aegis Capital analyst Nathan Weinstein initiates coverage on Evogene Ltd (NASDAQ: EVGN) with a Buy rating and a price target of $10.00.

Analyst comments: "Our price target is based on a discounted cash flow valuation, crediting key Evogene subsidiaries and lead programs, while treating others as option value at this time. Risks include: 1) clinical; 2) financial; 3) regulatory; 4) competition; 5) operational; and 6) other."

For an analyst ratings summary and ratings history on Evogene Ltd click here. For more ratings news on Evogene Ltd click here.

Shares of Evogene Ltd closed at $2.94 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage